Can You Lower Lp(a)? What the 2026 Drug Pipeline Means for You

If you've found out your Lp(a) is high — or you've read headlines about pelacarsen and olpasiran — the natural next question is: can I lower it? Here's the honest answer as of 2026, and the more useful one: what you can actually do about high Lp(a) right now.

Why you can't just diet or exercise it away

Lp(a) is unusual among cardiovascular numbers: it's set largely by the gene you inherited, it stays fairly stable across your life, and it barely responds to the things that move the rest of your lipid panel. Eating well, exercising, and losing weight are all worth doing — but they won't meaningfully change your Lp(a). That isn't a personal failing; it's biology. It's also exactly why researchers have spent years developing drugs aimed specifically at Lp(a). New to Lp(a)? Start with the complete guide →

What the drug pipeline actually is — and isn't

The new Lp(a) drugs work differently from statins. Instead of clearing cholesterol, they quiet the gene that produces the apo(a) protein, cutting how much Lp(a) your liver makes. In early studies, some lowered Lp(a) dramatically. But there's a crucial distinction a lot of headlines blur:

Status as of 2026. All are investigational — not approved, not available by prescription for lowering Lp(a). Named for information only; this is not a recommendation, and CardioIQ has no affiliation with any manufacturer. A closer look at pelacarsen & olpasiran →

What about statins, niacin, or supplements?

A few things are worth clearing up, because they're common sources of confusion:

• Statins don't lower Lp(a) — and may nudge it up slightly. This is not a reason to avoid or stop them. Statins substantially lower ApoB and your overall cardiovascular risk, which matters a great deal when your Lp(a) is high. Any decision about statins belongs with your physician, weighed across your whole risk — not on the Lp(a) number alone.
• PCSK9 inhibitors lower Lp(a) modestly as a side effect, but they aren't approved for that purpose, and there's no Lp(a)-specific outcome evidence behind it. A physician decision, based on your broader risk.
• Niacin lowers Lp(a) a little but hasn't shown a meaningful reduction in cardiovascular events — so it isn't recommended for this.
• Supplements have no good evidence for lowering Lp(a) or the risk it carries. Save your money.

So what can you actually do today?

This is the part that matters, and it's genuinely empowering: a high Lp(a) raises your risk, but it's rarely acting alone — and everything around it is highly modifiable. The goal shifts from “lower the Lp(a)” to “lower your total risk, so the Lp(a) has less to add to.”

1. Measure it once, properly. If you haven't had Lp(a) tested, do it — a single measurement usually tells you your lifelong level. Reading it against optimal targets (not just a lab “normal”) is where the interpretation matters. High Lp(a): what targets to aim for →
2. Drive everything else to optimal. With Lp(a) high, getting your ApoB and LDL to an ambitious, physician-set target does more of the work — because your total atherogenic burden is what your arteries actually see. This is the single highest-leverage move available now.
3. Control blood pressure, metabolic health, and smoking. Each independently compounds cardiovascular risk. When one risk factor is fixed by genetics, tightening the modifiable ones counts for more, not less.
4. Screen your family. Lp(a) is inherited, so a high result is information for your relatives too — first-degree family members may benefit from their own one-time test.
5. Talk to your physician about the horizon. That includes whether a clinical trial is appropriate for you, whether lipoprotein apheresis has any role in select very-high-risk cases, and keeping watch as trial data matures. These are decisions to make together.